Hedgehog pathway inhibitors 

The Hedgehog pathway plays an essential role in cell growth and differentiation in the developing embryo. It is typically silenced in adult tissues. In postembryonic life, the pathway may be activated to stimulate tissue repair or cell proliferation. Abnormal activation may lead to cancer, including basal cell carcinoma. Hedgehog pathway inhibitors target the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors. Hedgehog pathway inhibitors may be used to treat basal cell carcinoma that has spread to other parts of the body.

At least three Hedgehog pathway inhibitors have been approved by the Food and Drug Administration (FDA) for cancer treatment. These include vismodegib and sonidegib, both inhibitors of Smoothened (SMO), which are being used for the treatment of basal cell carcinoma.

This can be prevented by using drugs known as Hedgehog pathway inhibitors (HHIs) such as vismodegib and sonidegib. While HHIs are effective treatments for advanced BCC, they are associated with significant toxicities.